Global Single-use Bioreactors Market to Cross ~USD 10 Billion Mark by 2032 | DelveInsight

The widespread adoption of single-use technologies, particularly in biopharmaceutical manufacturing, is fueled by their adaptability and efficiency. They enable swift setup for multiple processes, addressing the increasing demand for diverse bioproducts. Additionally, the reduced risk of cross-contamination between batches enhances product safety and quality—an essential factor in regulated environments—while also lowering costs associated with cleaning and validation.

/EIN News/ -- New York, USA, March 06, 2025 (GLOBE NEWSWIRE) -- Global Single-use Bioreactors Market to Cross ~USD 10 Billion Mark by 2032 | DelveInsight

The widespread adoption of single-use technologies, particularly in biopharmaceutical manufacturing, is fueled by their adaptability and efficiency. They enable swift setup for multiple processes, addressing the increasing demand for diverse bioproducts. Additionally, the reduced risk of cross-contamination between batches enhances product safety and quality—an essential factor in regulated environments—while also lowering costs associated with cleaning and validation.

DelveInsight’s Single-use Bioreactors Market Insights report provides the current and forecast market analysis, individual leading single-use bioreactors companies’ market shares, challenges, single-use bioreactors market drivers, barriers, trends, and key market single-use bioreactors companies in the market.

Key Takeaways from the Single-use Bioreactors Market Report

• As per DelveInsight estimates, North America is anticipated to dominate the global single-use bioreactors market during the forecast period. 
• In the capacity segment of the single-use bioreactors market, bioreactors exceeding 1,500 liters captured a significant revenue share in 2024.
• Notable single-use bioreactors companies such as Getinge AB, Agilitech, WuXi Biologics, mAbxience, Eppendorf AG, Sartorius AG, Cytiva Life Sciences, Merck KGaA, Bionet, OmniBRx Biotechnologies, Thermo Fisher Scientific Inc., Pall Corporation, Distek, Inc., AGC Biologics, Celltainer, Applikon Biotechnology, Biolinx Labsystems, Sartorius Stedim Biotech, Solaris Biotech, Synthecon, and several others, are currently operating in the single-use bioreactors market.
• In March 2024, Getinge AB extended the bioreactor portfolio with larger single-use systems.
• In September 2023, Getinge AB launched a single-use bioreactor for clinical cell and gene therapies.

To read more about the latest highlights related to the single-use bioreactors market, get a snapshot of the key highlights entailed in the Global Single-use Bioreactors Market Report

Single-use Bioreactors Overview

Single-use bioreactors (SUBs) are disposable bioprocessing systems used for cell culture and fermentation in the biopharmaceutical industry. Unlike traditional stainless-steel bioreactors, SUBs use pre-sterilized plastic bags as the cultivation vessel, eliminating the need for extensive cleaning and sterilization between batches. This significantly reduces downtime, lowers contamination risks, and improves operational flexibility. They are particularly beneficial for small-batch production, process development, and personalized medicine applications. SUBs have gained popularity in monoclonal antibody production, cell and gene therapy, and vaccine manufacturing due to their ability to support rapid scale-up and reduce capital expenditure.  

Despite their advantages, SUBs have limitations, including concerns about scalability, plastic waste generation, and potential leachables from the plastic materials. While they are effective for volumes up to 2,000 liters, larger-scale production still relies on traditional stainless-steel systems. Additionally, regulatory compliance and supply chain stability for single-use components are critical considerations for manufacturers. Innovations in bioprocessing, such as hybrid systems combining SUBs with stainless steel, aim to balance flexibility with sustainability. As the biopharmaceutical industry continues to evolve, the adoption of SUBs is expected to increase, driven by advancements in bioprocess technology and the growing demand for cost-effective, agile manufacturing solutions.

Single-use Bioreactors Market Insights

North America dominated the global single-use bioreactors market in 2024, driven by its strong biopharmaceutical industry. Major players like Pfizer, Moderna, and Amgen are at the forefront of adopting advanced bioprocessing technologies, fueled by the rising demand for biologics, cell and gene therapies, and personalized medicine. The region’s focus on flexible manufacturing solutions makes single-use bioreactors an attractive choice due to their efficiency and adaptability.  

Regulatory bodies such as the FDA play a crucial role in fostering innovation, while the presence of leading manufacturers and research institutions accelerates product development. Additionally, increasing investments in biotechnology infrastructure and a growing number of clinical trials are boosting the demand for scalable and cost-effective production technologies.  

The widespread adoption of single-use bioreactors in North America is attributed to their flexibility, scalability, and operational efficiency. Biopharmaceutical companies benefit from quicker production setups, seamless batch transitions, and reduced contamination risks, ensuring product safety and quality in highly regulated environments. Unlike conventional stainless-steel systems that require extensive cleaning and sterilization, single-use bioreactors minimize downtime and lower operational costs, making them particularly appealing to contract manufacturing organizations (CMOs) and smaller biotech firms.  

With the industry shifting towards smaller batch sizes and continuous processing, single-use bioreactors provide the adaptability needed to meet evolving production demands. Market expansion in the U.S. is further supported by ongoing product innovations. For instance, in October 2021, Agilitech, a U.S.-based company, introduced a bioreactor controller capable of managing up to two single-use bioreactors with capacities between 30 L and 2,000 L. Its versatile design ensures compatibility with multiple bioreactor brands, reflecting the industry's commitment to enhancing manufacturing flexibility.  

Overall, these factors are expected to drive substantial growth in the North American single-use bioreactors market throughout the forecast period.

To know more about why North America is leading the market growth in the single-use bioreactors market, get a snapshot of the Single-use Bioreactors Market Outlook 

Single-use Bioreactors Market Dynamics

The single-use bioreactors market has witnessed significant growth over the past decade, driven by increasing adoption in biopharmaceutical manufacturing. The shift from traditional stainless steel bioreactors to disposable systems is primarily fueled by the demand for cost reduction, flexibility, and impro

ved efficiency in biologics production. As biopharma companies increasingly focus on monoclonal antibodies (mAbs), cell therapies, and gene therapies, single-use systems are becoming the preferred choice due to their ability to minimize contamination risks and accelerate production timelines.

One of the key drivers of the SUB market is the rising investment in biologics and biosimilars. With regulatory agencies pushing for faster approvals and cost-effective manufacturing, biopharma companies are leveraging single-use technologies to streamline processes and reduce capital expenditures. Additionally, CDMOs are major adopters of SUBs, as these systems allow them to handle multiple projects with different process requirements without extensive cleaning and validation procedures.

Despite its advantages, the single-use bioreactor market faces challenges, including concerns about scalability and plastic waste disposal. While SUBs are widely used in early-stage development and clinical manufacturing, large-scale commercial production still relies on traditional stainless steel bioreactors due to volume limitations. Additionally, sustainability concerns regarding the disposal of plastic-based bioreactors have prompted industry players to explore recycling initiatives and biodegradable alternatives.

Technological advancements, such as improved sensor integration, automation, and hybrid bioreactor systems (combining single-use and stainless steel), are shaping the future of the market. Innovations in bioreactor design are enhancing process control and data analytics, making SUBs more viable for large-scale operations. Companies are also investing in high-density cell culture technologies to maximize productivity in smaller bioreactors.

Looking ahead, the single-use bioreactors market is poised for continued expansion, particularly in emerging markets where biopharmaceutical infrastructure is growing. The increasing adoption of continuous bioprocessing and intensified upstream processing is expected to further boost demand. As the industry addresses scalability and sustainability challenges, the next wave of innovation will likely focus on optimizing single-use systems for commercial-scale production while minimizing environmental impact.

Get a sneak peek at the single-use bioreactors market dynamics @ Single-use Bioreactors Market Dynamics Analysis

Report Metrics	Details
Coverage	Global
Study Period	2022–2032
Single-use Bioreactors Market CAGR	~16%
Single-use Bioreactors Market Size by 2032	~USD 10 Billion
Key Single-use Bioreactors Companies	Getinge AB, Agilitech, WuXi Biologics, mAbxience, Eppendorf AG, Sartorius AG, Cytiva Life Sciences, Merck KGaA, Bionet, OmniBRx Biotechnologies, Thermo Fisher Scientific Inc., Pall Corporation, Distek, Inc., AGC Biologics, Celltainer, Applikon Biotechnology, Biolinx Labsystems, Sartorius Stedim Biotech, Solaris Biotech, Synthecon, among others

Single-use Bioreactors Market Assessment

• Single-use Bioreactors Market Segmentation
  • Single-use Bioreactors Market Segmentation By Capacity: ≤10 L, 11–100 L, 101–500 L, 501–1,500 L, and Above 1,500 L
  • Single-use Bioreactors Market Segmentation By Product: System and Accessories
  • Single-use Bioreactors Market Segmentation By Type: Stirred Tank Bioreactors, Wave-Induced Bioreactors, Bubble-Column Bioreactors, and Others
  • Single-use Bioreactors Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of World
• Porter’s Five Forces Analysis, Product Profiles, Case Studies, KOL’s Views, Analyst’s View

Which MedTech key players in the single-use bioreactors market are set to emerge as the trendsetter explore @ Single-use Bioreactors Companies 

Table of Contents 

1	Single-use Bioreactors Market Report Introduction
2	Single-use Bioreactors Market Executive Summary
3	Competitive Landscape
4	Regulatory Analysis
5	Single-use Bioreactors Market Key Factors Analysis
6	Single-use Bioreactors Market Porter’s Five Forces Analysis
7	Single-use Bioreactors Market Layout
8	Single-use Bioreactors Market Company and Product Profiles
9	KOL Views
10	Project Approach
11	About DelveInsight
12	Disclaimer & Contact Us

Interested in knowing the single-use bioreactors market by 2032? Click to get a snapshot of the Single-use Bioreactors Market Trends

Related Reports

Contract Development Manufacturing Organization Market

Contract Development Manufacturing Organization Market Insights, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key CDMO companies, including Patheon (Thermo Fisher Scientific), Catalent,Inc, Laboratoire Elaiapharm, The Lubrizol Corporation, Cambrex Corporation, Recipharm (EQT), Merck & Co., Inc, AGC Biologics, Nerpharma S.r.l, Pfizer CenterOne (Pfizer Inc), EMERGENT, Onyx Scientific Limited, Lonza, Siegfried Holding AG, CordenPharma International, FUJIFILM Diosynth Biotechnologies, Samsung Biologics, Delpharm, Center for Breakthrough Medicines, and WuXi Biologics, among others.

Biopharmaceuticals Contract Manufacturing Market

Biopharmaceuticals Contract Manufacturing Market Insights, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key biopharmaceuticals contract manufacturing companies, including Boehringer Ingelheim International GmbH, Lonza, Rentschler Biopharma SE, BINEX Co., Ltd., INCOG BioPharma Service, FUJIFILM Diosynth Biotechnologies U.S.A. Inc., Novartis AG, ProBioGen AG, TOYOBO CO., LTD., Samsung Biologics, Thermo Fisher Scientific, Inc., AbbVie, Inc., WuXi Biologics, AGC Biologics, ADMA Biologics, Inc., Baxter BioPharma Solutions (Baxter), iBio., Catalent, Inc., Cambrex Corporation, Pfizer Inc., among others.

Biologics Drug Substance Fill and Finish Manufacturing Market

Biologics Drug Substance Fill and Finish Manufacturing Market Insight, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key biologics drug substance fill and finish manufacturing companies, including JOINN Biologics, Pharmaron, Symbiosis Pharmaceutical Services, AGC Biologics, INCOG BioPharma Services, CPC, Eurofins Scientific, among others.

Biologics Contract Manufacturing Market

Biologics Contract Manufacturing Market Insights, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key biologics contract manufacturing companies, including Boehringer Ingelheim, Catalent, Lonza, WuXi Biologics, Samsung Biologics, FUJIFILM Diosynth Biotechnologies, AbbVie, AGC Biologics, among others.

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.  

Contact Us
                    
                    Shruti Thakur 
                    
                    info@delveinsight.com 
                    
                    +14699457679
                    
                    https://www.delveinsight.com/medical-devices